329 related articles for article (PubMed ID: 30259082)
1. CD19
Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
[TBL] [Abstract][Full Text] [Related]
2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and Predictive Value of O
Zhang J; Zhu Y; Wang Y; Fu Q; Xie H; Liu Z; Fu H; Cao Y; Xu J; Dai B
Ann Surg Oncol; 2018 Jan; 25(1):342-348. PubMed ID: 29116491
[TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Xie H; Fu Q; Dai B; Ye D; Xu J
Clin Cancer Res; 2018 Jul; 24(13):3069-3078. PubMed ID: 29514839
[No Abstract] [Full Text] [Related]
5. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.
Eckstein M; Strissel P; Strick R; Weyerer V; Wirtz R; Pfannstiel C; Wullweber A; Lange F; Erben P; Stoehr R; Bertz S; Geppert CI; Fuhrich N; Taubert H; Wach S; Breyer J; Otto W; Burger M; Bolenz C; Keck B; Wullich B; Hartmann A; Sikic D;
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448798
[TBL] [Abstract][Full Text] [Related]
7. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
8. Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
Pagliarulo F; Cheng PF; Brugger L; van Dijk N; van den Heijden M; Levesque MP; Silina K; van den Broek M
Front Immunol; 2021; 12():793992. PubMed ID: 35145509
[TBL] [Abstract][Full Text] [Related]
9. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
10. Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer.
Zhou Q; Zhang H; Wang Z; Zeng H; Liu Z; Huang Q; Lin Z; Qu Y; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Dai B; Guo J; Zhu Y; Xu L; Xu J
Int J Cancer; 2020 Dec; 147(12):3539-3549. PubMed ID: 32734613
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.
Zeng H; Liu Z; Wang Z; Zhou Q; Qi Y; Chen Y; Chen L; Zhang P; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Int J Cancer; 2020 Jan; 146(2):542-552. PubMed ID: 31584197
[TBL] [Abstract][Full Text] [Related]
13. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.
Ye R; Zeng H; Liu Z; Jin K; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Wang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Feb; 71(2):301-310. PubMed ID: 34152439
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.
Yin M; Joshi M; Meijer RP; Glantz M; Holder S; Harvey HA; Kaag M; Fransen van de Putte EE; Horenblas S; Drabick JJ
Oncologist; 2016 Jun; 21(6):708-15. PubMed ID: 27053504
[TBL] [Abstract][Full Text] [Related]
15. B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
Xie H; Zhu Y; Zhang J; Liu Z; Fu H; Cao Y; Li G; Shen Y; Dai B; Xu J; Ye D
BMC Cancer; 2018 May; 18(1):590. PubMed ID: 29793447
[TBL] [Abstract][Full Text] [Related]
16. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer.
Benítez R; Yu K; Sirota M; Malats N; Pineda S
Front Immunol; 2023; 14():986598. PubMed ID: 36817478
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer.
Zhou L; Xu L; Chen L; Fu Q; Liu Z; Chang Y; Lin Z; Xu J
Oncoimmunology; 2017; 6(4):e1293211. PubMed ID: 28507798
[TBL] [Abstract][Full Text] [Related]
20. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
